Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200543648> ?p ?o ?g. }
- W4200543648 endingPage "2473" @default.
- W4200543648 startingPage "2459" @default.
- W4200543648 abstract "Oral squamous cell-carcinoma (OSCC) is a common cancer which arises from the alveolar ridge, buccal mucosa, and tongue. Among OSCC, the incidence of tongue squamous cell-carcinoma (TSCC) is growing all over the world. Oral carcinogenesis has been linked to genetic mutations, chromosomal aberrations and viral factors. Apoptosis and angiogenesis play a key role in the development of oral cancer. Therefore, it is very important discover new therapeutic strategies to counteract oral cancer progression. This study aimed to investigate the effect of KYP-2047 in an in vitro model of TSCC and in vivo CAL27-xenograft model. Our results demonstrated that KYP-2047 was able to reduce TSCCs cell viability at the concentrations of 50 μM and 100 μM. Additionally, KYP-2047 was able to increase Bax, Bad and caspase-3 expression, whereas Bcl-2 and p53 expression were reduced. Moreover, KYP-2047 significantly reduced vascular-endothelial-growth-factor (VEGF) and endothelial-nitric-oxide-synthase (eNOS) expression. In the vivo xenograft model, KYP-2047 at doses of 1 and 5 mg/kg significantly reduced tumor burden and tumor weight, decreasing also angiogenesis markers VEGF and eNOS. Moreover, KYP-2047 increased Bax and reduced Bcl2 expressions. Thus, KYP-2047 could represent a potential therapeutic treatment to counteract tongue oral-cancer growth, thanks its abilities to modulate angiogenesis and apoptosis pathways." @default.
- W4200543648 created "2021-12-31" @default.
- W4200543648 creator A5007489715 @default.
- W4200543648 creator A5012341521 @default.
- W4200543648 creator A5028276792 @default.
- W4200543648 creator A5030037474 @default.
- W4200543648 creator A5034178951 @default.
- W4200543648 creator A5038577140 @default.
- W4200543648 creator A5059107542 @default.
- W4200543648 creator A5063288145 @default.
- W4200543648 creator A5065961339 @default.
- W4200543648 creator A5068669980 @default.
- W4200543648 creator A5073045089 @default.
- W4200543648 date "2021-12-07" @default.
- W4200543648 modified "2023-09-27" @default.
- W4200543648 title "Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma" @default.
- W4200543648 cites W1487661483 @default.
- W4200543648 cites W1835826588 @default.
- W4200543648 cites W1968015782 @default.
- W4200543648 cites W1979405042 @default.
- W4200543648 cites W1980011561 @default.
- W4200543648 cites W1989566285 @default.
- W4200543648 cites W1998968327 @default.
- W4200543648 cites W2046848104 @default.
- W4200543648 cites W2063002895 @default.
- W4200543648 cites W2067862842 @default.
- W4200543648 cites W2070692994 @default.
- W4200543648 cites W2075637276 @default.
- W4200543648 cites W2084214834 @default.
- W4200543648 cites W2084831115 @default.
- W4200543648 cites W2091297212 @default.
- W4200543648 cites W2098360835 @default.
- W4200543648 cites W2110435930 @default.
- W4200543648 cites W2141848068 @default.
- W4200543648 cites W2147504123 @default.
- W4200543648 cites W2154007598 @default.
- W4200543648 cites W2157757288 @default.
- W4200543648 cites W2158025958 @default.
- W4200543648 cites W2158112993 @default.
- W4200543648 cites W2158517181 @default.
- W4200543648 cites W2168474143 @default.
- W4200543648 cites W2170718479 @default.
- W4200543648 cites W2205357811 @default.
- W4200543648 cites W2279794621 @default.
- W4200543648 cites W2298323837 @default.
- W4200543648 cites W2330056755 @default.
- W4200543648 cites W2413175500 @default.
- W4200543648 cites W2418692892 @default.
- W4200543648 cites W2549892900 @default.
- W4200543648 cites W2567989403 @default.
- W4200543648 cites W2588292388 @default.
- W4200543648 cites W2615483558 @default.
- W4200543648 cites W2741325805 @default.
- W4200543648 cites W2769336799 @default.
- W4200543648 cites W2793658375 @default.
- W4200543648 cites W2888446770 @default.
- W4200543648 cites W2897204809 @default.
- W4200543648 cites W2944196167 @default.
- W4200543648 cites W2947066396 @default.
- W4200543648 cites W2964225845 @default.
- W4200543648 cites W2965900368 @default.
- W4200543648 cites W2973887189 @default.
- W4200543648 cites W3004765289 @default.
- W4200543648 cites W3006059394 @default.
- W4200543648 cites W3006299065 @default.
- W4200543648 cites W3011444375 @default.
- W4200543648 cites W3039819529 @default.
- W4200543648 cites W3093781946 @default.
- W4200543648 cites W3094514903 @default.
- W4200543648 cites W3097610958 @default.
- W4200543648 cites W3098060537 @default.
- W4200543648 cites W3111252683 @default.
- W4200543648 cites W3128646645 @default.
- W4200543648 cites W3174662263 @default.
- W4200543648 cites W3178714668 @default.
- W4200543648 cites W4240716064 @default.
- W4200543648 cites W2909035731 @default.
- W4200543648 doi "https://doi.org/10.18632/oncotarget.28147" @default.
- W4200543648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34917264" @default.
- W4200543648 hasPublicationYear "2021" @default.
- W4200543648 type Work @default.
- W4200543648 citedByCount "3" @default.
- W4200543648 countsByYear W42005436482022 @default.
- W4200543648 countsByYear W42005436482023 @default.
- W4200543648 crossrefType "journal-article" @default.
- W4200543648 hasAuthorship W4200543648A5007489715 @default.
- W4200543648 hasAuthorship W4200543648A5012341521 @default.
- W4200543648 hasAuthorship W4200543648A5028276792 @default.
- W4200543648 hasAuthorship W4200543648A5030037474 @default.
- W4200543648 hasAuthorship W4200543648A5034178951 @default.
- W4200543648 hasAuthorship W4200543648A5038577140 @default.
- W4200543648 hasAuthorship W4200543648A5059107542 @default.
- W4200543648 hasAuthorship W4200543648A5063288145 @default.
- W4200543648 hasAuthorship W4200543648A5065961339 @default.
- W4200543648 hasAuthorship W4200543648A5068669980 @default.
- W4200543648 hasAuthorship W4200543648A5073045089 @default.
- W4200543648 hasBestOaLocation W42005436481 @default.
- W4200543648 hasConcept C121608353 @default.